Acute Hereditary Angioedema Attack Therapeutics
1. Ekterly patent expiration
Treatment: Treatment of acute attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11084809 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US10364238 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11001578 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11230537 | KALVISTA | NA |
Dec, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11198691 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US10611758 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11739068 | KALVISTA | NA |
Jun, 2037
(11 years from now) | |
| US11234939 | KALVISTA | NA |
Jan, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2030 |
Drugs and Companies using SEBETRALSTAT ingredient
NCE-1 date: 03 July, 2029
Market Authorisation Date: 03 July, 2025
Dosage: TABLET
More Information on Dosage
EKTERLY family patents
